16 https://ec.europa.eu/jrc/ ORG-0001 European Commission, DG JRC - Joint Research Centre Hermann-von-Helmholtz-Platz 1 JRC.G - Nuclear Safety and Security,JRC.G.5 - Nuclear Science and Innovation for Energy and Health Eggenstein-Leopoldshafen D-76344 DE123 DEU COM +32 2 299 11 11 jrc-procurement-karlsruhe@ec.europa.eu http://curia.europa.eu ORG-0002 Court of Justice of the European Union Rue du Fort Niedergrünewald Luxembourg L-2925 LU000 LUX CURIA +352 4303-1 GC.Registry@curia.europa.eu https://commission.europa.eu/ ORG-0003 European Commission Mondrian (CDMA), Rue du Champ de Mars 21 Brussels B-1050 BE100 BEL EUCOM +32 2 299 11 11 jrc-procurement-karlsruhe@ec.europa.eu 00500469-2026137/20262026-07-20+02:00 2.3 eforms-sdk-1.14 1eaa7845-ba95-420d-a6bc-6523f45c6895 a2c8b963-668e-4f26-8454-11db7332e942 2026-07-17+02:00 13:26:59+02:00 01 32024R2509 cn-standard ENG eu-ins-bod-ag gen-pub ORG-0001 ted-esen ORG-0003 epo-procurement-document For the full list of exclusion grounds please consult the procurement documents. neg-w-call false EC-JRC/KRU/2026/CPN/0562 Sale of 7.7 g of Radium-226 for medical applications The European Commission, Joint Research Centre (JRC) in Karlsruhe (Germany) plans to sell approximately 7.7 grams of Radium-226 (Ra-226), a valuable resource from its our strategic inventory utilised for cutting-edge research and development in nuclear medical applications. This includes applications in the production of Actinium-225 (Ac-225) for the use of targeted alpha therapy. Following a surge of demand for Ac-225, Ra-226 material serves as a crucial source material for producing it as well as other valuable medical radioisotopes, such as Lead-212 (Pb-212). With a growing demand and limited supply for Ra-226, the JRC Karlsruhe wants to contribute to the medical isotope supply chain. The expertise along with the state-of-the-art assets at JRC Karlsruhe, equips it to contribute effectively to this critical field. This sale is meant to bolster the availability of Ra-226 for medical applications and further the advancement of nuclear medicine. supplies In case of unavailability or disruptions in the functioning of the electronic means of communication provided in Section 5.1.11 in the last 5 calendar days before the time limit for receipt indicated in Section 5.1.12, the contracting authority reserves the right to extend this time limit and publish the extension at the Internet address provided in Section 5.1.11, without a preceding publication of a corrigendum to this notice. Economic operators interested in this procurement are invited to subscribe to the call for tenders at the address in Section 5.1.11 in order to get notified when new information or documents are published. true 09343000 Please consult the procurement documents. anyw-cou DEU LOT-0001 eu-funds default-text non-restricted-document ENG official https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/a2c8b963-668e-4f26-8454-11db7332e942-CN?#anchorDocuments epo-procurement-document none no allowed not-allowed true per-exa 100 price Please consult the procurement documents. https://webgate.ec.europa.eu/digit/opsys/esubmission?cftUuid=a2c8b963-668e-4f26-8454-11db7332e942 ORG-0001 ORG-0002 BUL CES DAN DEU ELL ENG SPA EST FIN FRA GLE HRV HUN ITA LIT LAV MLT NLD POL POR RON SLK SLV SWE true true Funding and Tenders Portal required true false https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/a2c8b963-668e-4f26-8454-11db7332e942-CN?#anchorDocuments 2026-09-18+02:00 12:00:59+02:00 783194-2024 false 3 false none none EC-JRC/KRU/2026/CPN/0562 Sale of 7.7 g of Radium-226 for medical applications The European Commission, Joint Research Centre (JRC) in Karlsruhe (Germany) plans to sell approximately 7.7 grams of Radium-226 (Ra-226), a valuable resource from its our strategic inventory utilised for cutting-edge research and development in nuclear medical applications. This includes applications in the production of Actinium-225 (Ac-225) for the use of targeted alpha therapy. Following a surge of demand for Ac-225, Ra-226 material serves as a crucial source material for producing it as well as other valuable medical radioisotopes, such as Lead-212 (Pb-212). With a growing demand and limited supply for Ra-226, the JRC Karlsruhe wants to contribute to the medical isotope supply chain. The expertise along with the state-of-the-art assets at JRC Karlsruhe, equips it to contribute effectively to this critical field. This sale is meant to bolster the availability of Ra-226 for medical applications and further the advancement of nuclear medicine. supplies 09343000 Please consult the procurement documents. anyw-cou DEU 36